Medicure vs. Hydrograph Clean Power: Most Important Chart

The most important chart to understand that Medicure (TSXV: MPH) is a real company that is a 100% sure thing to gain another 1,000% over the next twelve months vs. Hydrograph Clean Power (CSE: HG) being a 100% sure thing to decline another 90% over the next twelve months is the following chart of R&D expenditures. MPH was able to skip past Phase 1 and Phase 2 trials for MC-1 due to the massive investments previously made into the drug from 1997 through 2008 and now they are in Phase 3 trials and will receive an FDA Priority Review Voucher after receiving FDA approval that they will be able to sell for well over US$200 million:

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.